An open-label, phase 2 trial was conducted at 10 centers in France and enrolled patients with sympotomatic, measurable newly diagnosed multiple myeloma.
Researchers sought to determine whether adding ixazomib to treatment with lenalidomide plus dexamethasone would give a benefit to patients with newly diagnosed multiple myeloma.
